Dr Braunstein, when do you typically assess these patients for MRD status following their initial therapy? BRAUNSTEIN: I ...

In a real-world study involving patients with standard-risk, newly-diagnosed multiple myeloma (NDMM), there was no significant difference identified in the level of minimal residual disease (MRD) ...

A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

Chief Executive Officer of Legend Biotech. “MRD negativity is a prognostic marker of prolonged survival outcomes for patients with multiple myeloma. The significantly increased overall and ...

According to a new market research report, 'Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis ...

The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...

Minimal residual disease (MRD): remaining microscopic traces of tumor cells ... of Bone Marrow Transplant and Cellular Therapies and director of the Multiple Myeloma Programs at Fox Chase Cancer ...

SEQ is the first and only assay to receive Medicare coverage for MRD assessment in MCLCoverage leverages new Medicare episode pricing ...

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of CARVYKTI to transform outcomes in refractory multiple myeloma ...